Gastrointestinal Stromal Tumors - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Gastrointestinal Stromal Tumors - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Gastrointestinal Stromal Tumors: Overview
Gastrointestinal stromal tumors (GISTs) are among a group of cancers known as sarcomas. GISTs belong to the family of sarcomas, which are malignant tumors that arise from various tissues, including fat, muscle, nerves, cartilage, bone, blood vessels, and lymphatic vessels. This distinguishes sarcomas from carcinomas, which arise from the lining of organs/tissues (e.g., lung, colon, breast, prostate, and pancreas), lymphomas, which arise from immune cells in lymph nodes, and leukemias, which arise from immune cells in the bone marrow. GIST can present with a wide spectrum of subjective symptoms, such as nausea, early satiety, bloating, and weight loss. Patients can also experience objective signs of a tumor, such as anemia (low red blood cell count) or a lump in the abdomen. These signs and symptoms depend on the tumor location (e.g., stomach versus rectum), size, and pattern of growth.
'Gastrointestinal Stromal Tumors - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastrointestinal Stromal Tumors pipeline landscape is provided which includes the disease overview and Gastrointestinal Stromal Tumors treatment guidelines. The assessment part of the report embraces, in depth Gastrointestinal Stromal Tumors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastrointestinal Stromal Tumors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Gastrointestinal Stromal Tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gastrointestinal Stromal Tumors Emerging Drugs
Further product details are provided in the report
Gastrointestinal Stromal Tumors: Therapeutic Assessment
This segment of the report provides insights about the different Gastrointestinal Stromal Tumors drugs segregated based on following parameters that define the scope of the report, such as:
Gastrointestinal Stromal Tumors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastrointestinal Stromal Tumors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastrointestinal Stromal Tumors drugs.
Gastrointestinal Stromal Tumors Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Gastrointestinal Stromal Tumors - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Gastrointestinal Stromal Tumors: Overview
Gastrointestinal stromal tumors (GISTs) are among a group of cancers known as sarcomas. GISTs belong to the family of sarcomas, which are malignant tumors that arise from various tissues, including fat, muscle, nerves, cartilage, bone, blood vessels, and lymphatic vessels. This distinguishes sarcomas from carcinomas, which arise from the lining of organs/tissues (e.g., lung, colon, breast, prostate, and pancreas), lymphomas, which arise from immune cells in lymph nodes, and leukemias, which arise from immune cells in the bone marrow. GIST can present with a wide spectrum of subjective symptoms, such as nausea, early satiety, bloating, and weight loss. Patients can also experience objective signs of a tumor, such as anemia (low red blood cell count) or a lump in the abdomen. These signs and symptoms depend on the tumor location (e.g., stomach versus rectum), size, and pattern of growth.
'Gastrointestinal Stromal Tumors - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastrointestinal Stromal Tumors pipeline landscape is provided which includes the disease overview and Gastrointestinal Stromal Tumors treatment guidelines. The assessment part of the report embraces, in depth Gastrointestinal Stromal Tumors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastrointestinal Stromal Tumors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Gastrointestinal Stromal Tumors R&D. The therapies under development are focused on novel approaches to treat/improve Gastrointestinal Stromal Tumors.
This segment of the Gastrointestinal Stromal Tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gastrointestinal Stromal Tumors Emerging Drugs
- Famitinib: Jiangsu Hengrui Medicine
- DS 6157: Daiichi Sankyo Company
Further product details are provided in the report
Gastrointestinal Stromal Tumors: Therapeutic Assessment
This segment of the report provides insights about the different Gastrointestinal Stromal Tumors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Gastrointestinal Stromal Tumors
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Gastrointestinal Stromal Tumors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastrointestinal Stromal Tumors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastrointestinal Stromal Tumors drugs.
Gastrointestinal Stromal Tumors Report Insights
- Gastrointestinal Stromal Tumors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Gastrointestinal Stromal Tumors drugs?
- How many Gastrointestinal Stromal Tumors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastrointestinal Stromal Tumors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gastrointestinal Stromal Tumors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gastrointestinal Stromal Tumors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Jiangsu Hengrui Medicine
- Daiichi Sankyo Company
- Cogent Biosciences
- Advenchen Laboratories
- Chia Tai Tianqing Pharmaceutical Group
- AB Science
- Immunicum AB
- Novartis
- Bristol-Myers Squibb
- Hanmi Pharmaceutical Company Limited
- GlaxoSmithKline
- Ascentage Pharma
- Takeda
- Array BioPharma
- Plexxikon
- Arog Pharmaceuticals
- Xencor, Inc.
- DNAtrix, Inc.
- Taiho Pharmaceutical
- Onyx Pharmaceuticals
- Exelixis
- Allarity Therapeutics
- Famitinib
- DS 6157
- PLX9486
- Anlotinib
- Masitinib
- Intuvax
- Dovitinib
- Ipilimumab
- L-carnitine
- Pazopanib
- Nilotinib
- HQP1351
- PDR001
- Ponatinib
- MEK162
- Crenolanib besylate
- XmAb18087
- TNO155
- DNX-2440
- Pimitespib
- Palbociclib
- Cabozantinib
- Pamufetini
Introduction
Executive Summary
Gastrointestinal Stromal Tumors: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Gastrointestinal Stromal Tumors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Gastrointestinal Stromal Tumors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Gastrointestinal Stromal Tumors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Famitinib: Jiangsu Hengrui Medicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
DS 6157: Daiichi Sankyo Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Gastrointestinal Stromal Tumors Key Companies
Gastrointestinal Stromal Tumors Key Products
Gastrointestinal Stromal Tumors- Unmet Needs
Gastrointestinal Stromal Tumors- Market Drivers and Barriers
Gastrointestinal Stromal Tumors- Future Perspectives and Conclusion
Gastrointestinal Stromal Tumors Analyst Views
Gastrointestinal Stromal Tumors Key Companies
Appendix
Executive Summary
Gastrointestinal Stromal Tumors: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Gastrointestinal Stromal Tumors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Gastrointestinal Stromal Tumors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Gastrointestinal Stromal Tumors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Famitinib: Jiangsu Hengrui Medicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
DS 6157: Daiichi Sankyo Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Gastrointestinal Stromal Tumors Key Companies
Gastrointestinal Stromal Tumors Key Products
Gastrointestinal Stromal Tumors- Unmet Needs
Gastrointestinal Stromal Tumors- Market Drivers and Barriers
Gastrointestinal Stromal Tumors- Future Perspectives and Conclusion
Gastrointestinal Stromal Tumors Analyst Views
Gastrointestinal Stromal Tumors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Gastrointestinal Stromal Tumors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Gastrointestinal Stromal Tumors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Gastrointestinal Stromal Tumors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Gastrointestinal Stromal Tumors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
